Star Therapeutics Presents Clinical Data for VGA039, a Subcutaneous Therapy for the Treatment of Von Willebrand Disease (VWD)

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies, today announced the presentation of clinical data from VIVID 1 (VGA039 Investigation in Von Willebrand Disease), a Phase 1 clinical study of VGA039 in healthy volunteers. VGA039 is designed to be a universal hemostatic therapy for numerous bleeding disorders and potentially the first subcutaneous therapy for von Willebrand disease (VWD). Th
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks